Audentes Therapeutics Inc
Most Recent
Analysts Remain Bullish on BioMarin Pharmaceutical
Of the 23 analysts covering BioMarin Pharmaceutical (BMRN) in September, 19 of them have given the stock a “buy” or higher rating.
Audentes Therapeutics’ Promising Product Pipeline
In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.
Analyzing Audentes Therapeutics’ Valuation Metrics
Audentes Therapeutics (BOLD) incurred a net loss of $31.37 million in the second quarter compared with $22.74 million in Q2 2017.